Nuvation Bio Inc. (NUVB)

Biopharmaceutical company developing therapies for oncology and autoimmune diseases.

NUVB Stock Quote

Company Report

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is dedicated to developing innovative therapeutic candidates for oncology. The company's lead product candidate, NUV-422, is a small molecule inhibitor targeting cyclin-dependent kinases (CDK)2, CDK4, and CDK6, which are critical in regulating the cell cycle and are implicated in various cancers.

Additionally, Nuvation Bio is developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins controlling tumor growth and differentiation. Another promising candidate is NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase, which plays a crucial role in DNA damage repair.

The company's pipeline also includes NUV-1182, an adenosine receptor inhibitor, and a drug-drug conjugate (DDC) platform. This DDC platform focuses on targeting poly ADP ribose polymerase (PARP) inhibitors to anti-cancer warheads of existing drugs, aiming to address ER+ breast and ovarian cancer.

Nuvation Bio Inc. was formerly known as RePharmation Inc. and underwent a name change in April 2019. Founded in 2018, the company is headquartered in New York, New York, and continues to advance its portfolio of oncology treatments through cutting-edge research and development.

NUVB EPS Chart

NUVB Revenue Chart

Stock Research

FL KTB NCRA TRNR ESAC PDFS BSVN

NUVB Chart

View interactive chart for NUVB

NUVB Profile

NUVB News

Analyst Ratings